Injection-site rotation tracker

Where should I inject this week?

Log your last few injections by site; the tracker returns the next recommended site per the FDA-label §2.3 rotation rule for Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda. Works for compounded semaglutide and tirzepatide too (same molecule, same rotation rule). Includes a body diagram and a printable rotation card you can keep on the fridge.

Injection-site rotation inputs

Log a recent injection

Next suggested site

Abdomen (left)

Starting fresh — abdomen (left) is the most commonly cited first-injection site in the patient instructions for use, but any of the three regions is FDA-label compliant.

FDA-label rule (§2.3)

“Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each weekly dose.”

  • Leave at least 2 inches between sites
  • Stay at least 2 inches away from the navel on the abdomen
  • Avoid skin that is tender, bruised, red, hard, or scarred

Body diagram

Upper arm LUpper arm RAbdo Lleft of navelAbdo Rright of navelThigh Lupper outerThigh Rupper outerNext suggestedMost recentRecent

Sourced from the FDA-approved labeling at our injection-site guide. Educational — not a substitute for the patient instructions for use that came with your pen or vial.

The FDA-label rule

Every FDA-approved injectable GLP-1 ships with a §2.3 Important Administration Instructions section. The wording is nearly identical across Wegovy[1], Ozempic[2], Zepbound[3], Mounjaro[4], and Saxenda[5]:

Inject [drug] subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each [weekly/daily] dose.

The label does not specify a minimum inter-site distance, but the patient instructions for use that ship with each pen recommend keeping at least 2 inches between adjacent sites, avoiding a 2-inch radius around the navel on the abdomen, and skipping any patch of skin that is tender, bruised, red, hard, scarred, or has stretch marks.

Why rotate

  • Avoid lipohypertrophy. Repeated injection into the same site causes lipohypertrophy (fatty lumps under the skin) that change the drug’s absorption profile and can blunt the dose effect. Rotation is the standard prevention.
  • Avoid local injection-site reactions. Most site reactions (redness, itching, induration) resolve within a few days; rotating sites prevents stacked reactions on the same patch of skin.
  • Consistent absorption. The 3 body regions absorb at similar rates clinically, but rotating reduces site-specific variability that can otherwise creep into the curve over months of therapy.

The 3 regions and their landmarks

  • Abdomen — anywhere on the abdomen except within 2 inches (~5 cm) of the navel. Left and right of the navel are the canonical first-line sites in most patient instructions for use.
  • Thigh — upper outer thigh (front-outer aspect of the upper leg). Avoid the inner thigh near the femoral vessels.
  • Upper arm — the back of the upper arm (the triceps region). Usually requires another person to inject — the geometry is awkward for self-administration.

The rotation algorithm this tracker uses

The tracker reads your last 3 logged doses, identifies which regions have been used most recently, and picks the next site using two rules in order:

  1. Prefer a region that was not used in the last 3 doses.
  2. Within the chosen region, pick the side opposite the most recent dose in that region (or the opposite side of the most recent dose overall if the region is brand new for you).

The result is a 6-site cycle (3 regions × 2 sides) that typically rotates through all 6 in 6 doses on a weekly schedule, then repeats.

How to use the printable rotation card

The print / save / copy panel below the result bundles your drug, your most recent 6 logged doses, the next suggested site, and the FDA-label rotation rule into a one-page card you can stick on the fridge or save to your phone’s files. When you do this week’s injection, come back, log it, and reprint.

Related tools and research

Important disclaimer

This tracker is educational. The FDA-label §2.3 instructions and the patient instructions for use that came with your pen are the authoritative reference. If you have lipohypertrophy, persistent injection-site reactions, or any other site-related concern, contact your prescribing clinician or pharmacist.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, §2.3 Important Administration Instructions (subcutaneous injection in abdomen / thigh / upper arm; rotate sites). DailyMed (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Novo Nordisk Inc. OZEMPIC (semaglutide) injection — US Prescribing Information, §2.3 Important Administration Instructions. DailyMed (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  3. 3.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, §2.3 Important Administration Instructions. DailyMed (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-c1ee-4f60-b6cf-5f3aab1b86a4
  4. 4.Eli Lilly and Company. MOUNJARO (tirzepatide) injection — US Prescribing Information, §2.3 Important Administration Instructions. DailyMed (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. 5.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information, §2.3 Important Administration Instructions. DailyMed (FDA-approved labeling). 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143